Literature DB >> 8400919

Prostaglandin E2 increased rat cortical bone mass when administered immediately following ovariectomy.

H Z Ke1, W S Jee, Q Q Zeng, M Li, B Y Lin.   

Abstract

To investigate the effects of ovariectomy and the simultaneous administration of prostaglandin E2 (PGE2) on rat tibial shaft cortical bone histomorphometry, thirty-five 3-month-old female Sprague-Dawley rats were either ovariectomized (OVX), or sham ovariectomy (sham-OVX). The OVX rats were divided into three groups and treated with 0, 1 and 6 mg PGE2/kg/day for 90 days. The double fluorescent labeled undecalcified tibial shaft cross sections (proximal to the tibiofibular junction) of all the subjects were used for histomorphometry analysis. No differences in cross-sectional area and cortical bone area were found between sham-OVX and OVX controls, but OVX increased marrow area, intracortical porosity area and endocortical eroded perimeter. Periosteal and endocortical bone formation rates decreased with aging yet OVX prevented these changes. These OVX-induced increases in marrow area and endocortical eroded perimeter were prevented by 1 mg PGE2/kg/day treatment and added bone to periosteal and endocortical surfaces and to the marrow cavity. At the 6 mg/kg/day dose level, PGE2-treated OVX rats increased total tissue area, cortical bone area, marrow trabecular bone area, minimal cortical width and intracortical porosity area, and decreased marrow area compared to basal, sham-OVX and OVX controls. In addition, periosteal bone formation was elevated in the 6 mg PGE2/kg/day-treated OVX rats compared to OVX controls. Endocortical eroded perimeter increased from basal and sham-OVX control levels, but decreased from OVX control levels in the 6 mg PGE2/kg/day-treated OVX rats. Our study confirmed that ovariectomy does not cause osteopenia in tibial shaft cortical bone in rats, but it does stimulate endocortical bone resorption and enlarges marrow area. The new findings from the present study demonstrate that PGE2 prevents the OVX-induced increases in endocortical bone resorption and marrow area and adds additional bone to periosteal and endocortical surfaces and to marrow cavity to increase total bone mass in the tibial shaft of OVX rats when given immediately following ovariectomy.

Entities:  

Keywords:  NASA Discipline Musculoskeletal; NASA Discipline Number 26-10; NASA Program Space Physiology and Countermeasures; Non-NASA Center

Mesh:

Substances:

Year:  1993        PMID: 8400919     DOI: 10.1016/s0169-6009(08)80230-9

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  6 in total

1.  In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss.

Authors:  S Hu; C C Liu; G Chen; T Willett; R N Young; M D Grynpas
Journal:  Osteoporos Int       Date:  2015-08-14       Impact factor: 4.507

Review 2.  Mechanotransduction and the functional response of bone to mechanical strain.

Authors:  R L Duncan; C H Turner
Journal:  Calcif Tissue Int       Date:  1995-11       Impact factor: 4.333

Review 3.  The laboratory rat as an animal model for osteoporosis research.

Authors:  Pavlos P Lelovas; Theodoros T Xanthos; Sofia E Thoma; George P Lyritis; Ismene A Dontas
Journal:  Comp Med       Date:  2008-10       Impact factor: 0.982

Review 4.  Ovariectomized rat model of osteoporosis: a practical guide.

Authors:  Nasibeh Yousefzadeh; Khosrow Kashfi; Sajad Jeddi; Asghar Ghasemi
Journal:  EXCLI J       Date:  2020-01-10       Impact factor: 4.068

5.  In Vivo Bone Effects of a Novel Bisphosphonate-EP4a Conjugate Drug (C3) for Reversing Osteoporotic Bone Loss in an Ovariectomized Rat Model.

Authors:  Zeeshan Sheikh; Gang Chen; Faik Al-Jaf; Marion Thévenin; Kate Banks; Michael Glogauer; Robert N Young; Marc D Grynpas
Journal:  JBMR Plus       Date:  2019-11-09

6.  Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography.

Authors:  J E M Brouwers; F M Lambers; J A Gasser; B van Rietbergen; R Huiskes
Journal:  Calcif Tissue Int       Date:  2008-02-20       Impact factor: 4.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.